glp 1 vs sglt2 weight loss GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on Inhibitors Combining glucagon-like peptide-1 receptor agonists

Treatment focuses on lifestyle modification, particularly weight loss of 710% of body weight, alongside managing associated conditions such as diabetes, hypertension, and high cholesterol with appropriate medications like metformin and statins

This review lays that out with fair-balance framing rather than a recommendation, current as of April 2026

Diabetes guidelines from major organizations support adding SGLT-2 inhibitors and/or GLP-1 agonists to metformin therapy for patients with type 2 diabetes and established CVD, 510 and most guidelines support their use in patients at high risk of cardiovascular events

A $145 to $149 membership roughly doubles the all-in to about $294 a month, before any dose increase